Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403).
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4681-4681
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 9123-9123
◽
Keyword(s):
2014 ◽
Vol 50
(5)
◽
pp. 953-962
◽
Keyword(s):
Keyword(s):
2013 ◽
Vol 16
(4)
◽
pp. 382-386
◽
Keyword(s):
2008 ◽
Vol 26
(36)
◽
pp. 5936-5942
◽
2015 ◽
Vol 33
(7_suppl)
◽
pp. 140-140
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 6155-6155
2011 ◽
Vol 29
(15_suppl)
◽
pp. 4524-4524
2011 ◽
Vol 29
(7_suppl)
◽
pp. 10-10
◽